NCT02742324View on ClinicalTrials.gov

Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 30, 2021

Study Completion Date

December 31, 2021

Conditions
Myelofibrosis
Interventions
DRUG

Ruxolotinib

Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.

DRUG

peg-IFN alpha -2a

Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.

Trial Locations (1)

37044

FILO French Innovative Leukemia Organization, Tours

All Listed Sponsors
lead

French Innovative Leukemia Organisation

OTHER

NCT02742324 - Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg | Biotech Hunter | Biotech Hunter